List view / Grid view

Articles

Drug Target Review Proteomics eBook 2023

22 December 2023 | By

Download now! Drug Target Review breaks down the potential of stem cells for personalised regenerative medicine, offering practical insights into their role in healthcare.

Women in STEM with Dr Catherine Sheehan

22 December 2023 | By

In this special December edition of Women in STEM, we are privileged to feature Dr Catherine Sheehan, a distinguished figure whose journey in the field of STEM has been marked by passion, resilience, and impactful contributions. We explore her experiences, challenges faced, and the transformative impact of her work in…

Drug Target Review – Issue 4 2023

21 December 2023 | By

A new Drug Target Review issue is now ready to download! This issue features articles on CRISPR, personalised medicine and screening.

The future of mRNA biology and AI convergence

21 December 2023 | By

In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process. mRNA biology holds immense potential with RNAi drugs in the market and mRNA vaccines showing promise, particularly…

The first major set of genetic associations found in long COVID

13 December 2023 | By

PrecisionLife’s Dr Sayoni Das, a computational biologist who leads the research and development of bioinformatics pipelines that generate biological insights from PrecisionLife’s core technology and support drug discovery programmes, details a new study. Using combinatorial analysis, genetic variants associated with long COVID have been identified and, furthermore, it has been…

The future of lymphoma treatment

12 December 2023 | By

In the current landscape of drug discovery, lymphoma poses a significant challenge and opportunity. Researchers are fervently exploring novel therapeutic avenues, such as Antibody-Drug Conjugates (ADCs), to address the complexities of lymphoma. ARC-02, a standout candidate, demonstrates enhanced efficacy and tolerability in lymphoma treatment. While eyeing a diverse ADC pipeline,…